1. Kaminski H, Fishman JA: The Cell Biology of Cytomegalovirus: Implications for Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2016, 16(8):2254-2269.
2. Dioverti MV, Razonable RR: Cytomegalovirus. Microbiology spectrum 2016, 4(4).
3. Dupont L, Reeves MB: Cytomegalovirus latency and reactivation: recent insights into an age old problem. Reviews in medical virology 2016, 26(2):75-89.
4. Poole E, Sinclair J: Sleepless latency of human cytomegalovirus. Medical microbiology and immunology 2015, 204(3):421-429.
5. Brinkmann MM, Dag F, Hengel H, Messerle M, Kalinke U, Cicin-Sain L: Cytomegalovirus immune evasion of myeloid lineage cells. Medical microbiology and immunology 2015, 204(3):367-382.
6. Kumar A, Herbein G: Epigenetic regulation of human cytomegalovirus latency: an update. Epigenomics 2014, 6(5):533-546.
7. Lancini D, Faddy HM, Flower R, Hogan C: Cytomegalovirus disease in immunocompetent adults. The Medical journal of Australia 2014, 201(10):578-580.
8. Fuji S, Einsele H, Kapp M: Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Current opinion in infectious diseases 2017, 30(4):372-376.
9. Zedtwitz-Liebenstein K, Diab-Elschahaw M, Frass M: Human Cytomegalovirus Infection in Nonimmunocompromised Patients: A Retrospective Analysis and Review of the Literature. Intervirology 2016, 59(3):159-162.
10. Al-Omari A, Aljamaan F, Alhazzani W, Salih S, Arabi Y: Cytomegalovirus infection in immunocompetent critically ill adults: literature review. Annals of intensive care 2016, 6(1):110.
11. Couzi L, Pitard V, Moreau JF, Merville P, Dechanet-Merville J: Direct and Indirect Effects of Cytomegalovirus-Induced gammadelta T Cells after Kidney Transplantation. Frontiers in immunology 2015, 6:3.
12. Egli A, Humar A, Kumar D: State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012, 55(12):1678-1689.
13. Hui J, Qu YY, Tang N, Liu YM, Zhong H, Wang LM, Feng Q, Li Z, He F: Association of cytomegalovirus infection with hypertension risk: a meta-analysis. Wiener klinische Wochenschrift 2016, 128(15-16):586-591.
14. Rector JL, Thomas GN, Burns VE, Dowd JB, Herr RM, Moss PA, Jarczok MN, Hoffman K, Fischer JE, Bosch JA: Elevated HbA(1c) levels and the accumulation of differentiated T cells in CMV(+) individuals. Diabetologia 2015, 58(11):2596-2605.
15. Wang H, Peng G, Bai J, He B, Huang K, Hu X, Liu D: Cytomegalovirus Infection and Relative Risk of Cardiovascular Disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): A Meta-Analysis of Prospective Studies Up to 2016. Journal of the American Heart Association 2017, 6(7).
16. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A: The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation 2018, 102(6):900-931.
17. Li TD, Li JJ, Huang X, Wang H, Guo XY, Ge SX, Zhang J: Baseline antibody level may help predict the risk of active human cytomegalovirus infection in a HCMV seropositive population. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2017, 36(5):863-868.
18. Shaiegan M, Rasouli M, Zadsar M, Zolfaghari S: Meta-analysis of cytomegalovirus seroprevalence in volunteer blood donors and healthy subjects in Iran from 1992 to 2013. Iranian journal of basic medical sciences 2015, 18(7):627-634.
19. Varghese J, Subramanian S, Reddy MS, Shanmugam N, Balajee G, Srinivasan V, Venkataraman J, Mohamed R: Seroprevalence of cytomegalovirus in donors & opportunistic viral infections in liver transplant recipients. The Indian journal of medical research 2017, 145(4):558-562.
20. Antona D, Lepoutre A, Fonteneau L, Baudon C, Halftermeyer-Zhou F, Y LES, Levy-Bruhl D: Seroprevalence of cytomegalovirus infection in France in 2010. Epidemiology and infection 2017, 145(7):1471-1478.
21. Anoh AE, Mossoun A, Akoua-Koffi C, Couacy-Hymann E, Pauly M, Leendertz SA, Kouakou N'goran E, Schubert G, Weiss S, Hofmann J et al: Seroprevalence of Cytomegalovirus Infection Among a Rural Population of Cote d'Ivoire. Viral immunology 2017, 30(1):54-57.
22. Hamprecht K, Bissinger AL, Arellano-Galindo J, Schweinzer K, Jiang X, Gohring K, Mikeler E, Jahn G: Intrafamilial transmission of human cytomegalovirus (HCMV): long-term dynamics of epitope-specific antibody response in context of avidity maturation. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2014, 60(2):119-126.
23. Torre-Cisneros J, Aguado JM, Caston JJ, Almenar L, Alonso A, Cantisan S, Carratala J, Cervera C, Cordero E, Farinas MC et al: Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplantation reviews (Orlando, Fla) 2016, 30(3):119-143.
24. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P: Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Reviews in medical virology 2019:e2034.
25. Kim J, Kim AR, Shin EC: Cytomegalovirus Infection and Memory T Cell Inflation. Immune network 2015, 15(4):186-190.
26. Klenerman P, Oxenius A: T cell responses to cytomegalovirus. Nature reviews Immunology 2016, 16(6):367-377.
27. Blum A, Peleg A, Weinberg M: Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis. Clinical and experimental medicine 2003, 3(3):157-160.
28. Blum A, Giladi M, Weinberg M, Kaplan G, Pasternack H, Laniado S, Miller H: High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. The American journal of cardiology 1998, 81(7):866-868.
29. Cannon MJ, Schmid DS, Hyde TB: Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Reviews in medical virology 2010, 20(4):202-213.
30. Seale H, MacIntyre CR, Gidding HF, Backhouse JL, Dwyer DE, Gilbert L: National serosurvey of cytomegalovirus in Australia. Clinical and vaccine immunology : CVI 2006, 13(11):1181-1184.
31. Korndewal MJ, Mollema L, Tcherniaeva I, van der Klis F, Kroes AC, Oudesluys-Murphy AM, Vossen AC, de Melker HE: Cytomegalovirus infection in the Netherlands: seroprevalence, risk factors, and implications. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2015, 63:53-58.
32. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ: Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006, 43(9):1143-1151.
33. Wang C, Dollard SC, Amin MM, Bialek SR: Cytomegalovirus IgM Seroprevalence among Women of Reproductive Age in the United States. PloS one 2016, 11(3):e0151996.
34. Hamprecht K, Goelz R: Postnatal Cytomegalovirus Infection Through Human Milk in Preterm Infants: Transmission, Clinical Presentation, and Prevention. Clinics in perinatology 2017, 44(1):121-130.
35. Varga M, Gorog D, Kari D, Kornyei E, Kis E, Turyne HJ, Jankovics I, Peter A, Toronyi E, Sarvary E et al: Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group. Transplantation proceedings 2011, 43(4):1233-1235.
36. Han SH: Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies. Infection & chemotherapy 2017, 49(3):161-175.
37. Yang TY, Chuang YF, Chiu YL: T-cell aging in end-stage renal disease: an evolving story with CMV. Medical microbiology and immunology 2019.
38. Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L: Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. Frontiers in immunology 2017, 8:131.
39. Sultan M, Ben-Ari Z, Masoud R, Pappo O, Harats D, Kamari Y, Safran M: Interleukin-1alpha and Interleukin-1beta play a central role in the pathogenesis of fulminant hepatic failure in mice. PloS one 2017, 12(9):e0184084.